148 related articles for article (PubMed ID: 34982568)
1. Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors.
Xue D; Xu Y; Kyani A; Roy J; Dai L; Sun D; Neamati N
J Med Chem; 2022 Jan; 65(1):343-368. PubMed ID: 34982568
[TBL] [Abstract][Full Text] [Related]
2. Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer.
Xue D; Xu Y; Kyani A; Roy J; Dai L; Sun D; Neamati N
J Med Chem; 2022 Feb; 65(4):3404-3419. PubMed ID: 35167303
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment.
He P; Bian A; Miao Y; Jin W; Chen H; He J; Li L; Sun Y; Ye J; Liu M; Yi Z; Zhou W; Chen Y
J Med Chem; 2022 Nov; 65(22):15487-15511. PubMed ID: 36282975
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic HSP60 regulates mitochondrial oxidative phosphorylation to support Erk1/2 activation during pancreatic cancer cell growth.
Zhou C; Sun H; Zheng C; Gao J; Fu Q; Hu N; Shao X; Zhou Y; Xiong J; Nie K; Zhou H; Shen L; Fang H; Lyu J
Cell Death Dis; 2018 Feb; 9(2):161. PubMed ID: 29415987
[TBL] [Abstract][Full Text] [Related]
5. Circumventing the Crabtree effect: forcing oxidative phosphorylation (OXPHOS) via galactose medium increases sensitivity of HepG2 cells to the purine derivative kinetin riboside.
Orlicka-Płocka M; Gurda-Wozna D; Fedoruk-Wyszomirska A; Wyszko E
Apoptosis; 2020 Dec; 25(11-12):835-852. PubMed ID: 32955614
[TBL] [Abstract][Full Text] [Related]
6. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
[TBL] [Abstract][Full Text] [Related]
7. ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer.
Ferrarini I; Louie A; Zhou L; El-Deiry WS
Mol Cancer Ther; 2021 Sep; 20(9):1572-1583. PubMed ID: 34224362
[TBL] [Abstract][Full Text] [Related]
8. 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
Buckley BJ; Aboelela A; Minaei E; Jiang LX; Xu Z; Ali U; Fildes K; Cheung CY; Cook SM; Johnson DC; Bachovchin DA; Cook GM; Apte M; Huang M; Ranson M; Kelso MJ
J Med Chem; 2018 Sep; 61(18):8299-8320. PubMed ID: 30130401
[TBL] [Abstract][Full Text] [Related]
9. Acinetobacter baumannii OxPhos inhibitors as selective anti-infective agents.
Rubin H; Selwood T; Yano T; Weaver DG; Loughran HM; Costanzo MJ; Scott RW; Wrobel JE; Freeman KB; Reitz AB
Bioorg Med Chem Lett; 2015 Jan; 25(2):378-83. PubMed ID: 25496770
[TBL] [Abstract][Full Text] [Related]
10. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
Lin L; Hutzen B; Li PK; Ball S; Zuo M; DeAngelis S; Foust E; Sobo M; Friedman L; Bhasin D; Cen L; Li C; Lin J
Neoplasia; 2010 Jan; 12(1):39-50. PubMed ID: 20072652
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship and mechanistic study on guggulsterone derivatives; Discovery of new anti-pancreatic cancer candidate.
Kohyama A; Kim MJ; Yokoyama R; Sun S; Omar AM; Phan ND; Meselhy MR; Tsuge K; Awale S; Matsuya Y
Bioorg Med Chem; 2022 Jan; 54():116563. PubMed ID: 34942553
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers.
Murase Y; Ono H; Ogawa K; Yoshioka R; Ishikawa Y; Ueda H; Akahoshi K; Ban D; Kudo A; Tanaka S; Tanabe M
Cancer Sci; 2021 Nov; 112(11):4641-4654. PubMed ID: 34510663
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Mitochondrial Transcription Inhibitors Active in Pancreatic Cancer Cells.
Chen W; Hu S; Mao S; Xu Y; Guo H; Li H; Paulsen MT; Chen X; Ljungman M; Neamati N
ChemMedChem; 2020 Nov; 15(21):2029-2039. PubMed ID: 32748543
[TBL] [Abstract][Full Text] [Related]
14. SR18292 exerts potent antitumor effects in multiple myeloma via inhibition of oxidative phosphorylation.
Xiang Y; Fang B; Liu Y; Yan S; Cao D; Mei H; Wang Q; Hu Y; Guo T
Life Sci; 2020 Sep; 256():117971. PubMed ID: 32553925
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
16. Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model.
Cai W; Ratnayake R; Gerber MH; Chen QY; Yu Y; Derendorf H; Trevino JG; Luesch H
Invest New Drugs; 2019 Apr; 37(2):364-374. PubMed ID: 30073464
[TBL] [Abstract][Full Text] [Related]
17. Targeting Oxidative Phosphorylation Reverses Drug Resistance in Cancer Cells by Blocking Autophagy Recycling.
Lee JS; Lee H; Jang H; Woo SM; Park JB; Lee SH; Kang JH; Kim HY; Song J; Kim SY
Cells; 2020 Sep; 9(9):. PubMed ID: 32883024
[TBL] [Abstract][Full Text] [Related]
18. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel 2-N-aryl-substituted benzenesulfonamidoacetamides: orally bioavailable tubulin polymerization inhibitors with marked antitumor activities.
Liu Z; Zhou Z; Tian W; Fan X; Xue D; Yu L; Yu Q; Long YQ
ChemMedChem; 2012 Apr; 7(4):680-93. PubMed ID: 22311585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
